The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Van Roy, Maarten ^a   Ververken, Cedric ^a   Beirnaert, Els ^a,b   Hoefman, Sven ^a   Kolkman, Joost ^a,c   Vierboom, Michel ^d   Breedveld, Elia ^d   't Hart, Bert ^d,e   Poelmans, Sofie ^a   Bontinck, Lieselot ^a   Hemeryck, Alex ^a   Jacobs, Sandy ^a   Baumeister, Judith ^a   Ulrichts, Hans ^a  

^a ABLYNX NV   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c CRUCELL HOLLAND BV   (Netherlands)

^d BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALX 0061; ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; FIBRINOGEN; INTERLEUKIN 6 RECEPTOR; NANOBODY; PLACEBO; SERUM ALBUMIN; TOCILIZUMAB; UNCLASSIFIED DRUG; ALX-0061; BISPECIFIC ANTIBODY; IL6 PROTEIN, HUMAN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 6;

ACUTE PHASE RESPONSE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; COLLAGEN-INDUCED ARTHRITIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; DRUG PROTEIN BINDING; ELIMINATION HALF-LIFE; IN VITRO STUDY; MACACA FASCICULARIS; MALE; NONHUMAN; PHARMACODYNAMICS; PLASMA HALF LIFE; RHESUS MONKEY; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; THROMBOCYTE COUNT; VOLUME OF DISTRIBUTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HALF LIFE TIME; HUMAN; IMMUNOLOGY;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIRHEUMATIC AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HALF-LIFE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; INTERLEUKIN-6; MACACA FASCICULARIS; MACACA MULATTA; RECEPTORS, INTERLEUKIN-6; SERUM ALBUMIN; SINGLE-DOMAIN ANTIBODIES;

EID: 84934900766     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0651-0     Document Type: Article

References (48)

1. Colmegna I, Ohata BR, Menard HA. Current understanding of rheumatoid arthritis therapy. Clin Pharmacol Ther. 2012;91:607-20.
2. Silman AJHM. Epidemiology of the rheumatic diseases. 2nd ed. New York: Oxford University Press; 2001.
3. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
4. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-75.
5. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51:v3-v11.
6. Dennis Jr G, Holweg CT, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, et al. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics. Arthritis Res Ther. 2014;16:R90.
7. Smolen JS, Schoels MM, Nishimoto N, Breedveld FC, Burmester GR, Dougados M, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis. 2013;72:482-92.
8. Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313.
9. Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis. 2011;2011:765624.
10. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta. 2011;1813:878-88.
11. Ferraccioli G, Bracci-Laudiero L, Alivernini S, Gremese E, Tolusso B, De Benedetti F. Interleukin-1beta and interleukin-6 in arthritis animal models: roles in the early phase of transition from acute to chronic inflammation and relevance for human rheumatoid arthritis. Mol Med. 2010;16:552-7.
12. Mimata Y, Kamataki A, Oikawa S, Murakami K, Uzuki M, Shimamura T, et al. Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Int J Rheum Dis. 2012;15:36-44.
13. Uchiyama Y, Yorozu K, Hashizume M, Moriya Y, Mihara M. Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis. Biol Pharm Bull. 2008;31:1159-63.
14. Hassanzadeh-Ghassabeh G, Devoogdt N, De Pauw P, Vincke C, Muyldermans S. Nanobodies and their potential applications. Nanomedicine (Lond). 2013;8:1013-26.
15. Unciti-Broceta JD, Del Castillo T, Soriano M, Magez S, Garcia-Salcedo JA. Novel therapy based on camelid nanobodies. Ther Deliv. 2013;4:1321-36.
16. Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775-97.
17. Bakker NP, van Erck MG, Otting N, Lardy NM, Noort RC, 't Hart BA, et al. Resistance to collagen-induced arthritis in a nonhuman primate species maps to the major histocompatibility complex class I region. J Exp Med. 1992;175:933-7.
18. Otting N, Heijmans CM, Noort RC, de Groot NG, Doxiadis GG, van Rood JJ, et al. Unparalleled complexity of the MHC class I region in rhesus macaques. Proc Natl Acad Sci U S A. 2005;102:1626-31.
19. Woo J, Vierboom MP, Kwon H, Chao D, Ye S, Li J, et al. PDL241, a novel humanized monoclonal antibody, reveals CD319 as a therapeutic target for rheumatoid arthritis. Arthritis Res Ther. 2013;15:R207.
20. Mihara M, Kotoh M, Nishimoto N, Oda Y, Kumagai E, Takagi N, et al. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys. Clin Immunol. 2001;98:319-26.
21. Hart BA, Bank RA, De Roos JA, Brok H, Jonker M, Theuns HM, et al. Collagen-induced arthritis in rhesus monkeys: evaluation of markers for inflammation and joint degradation. Br J Rheumatol. 1998;37:314-23.
22. Vierboom MP, Jonker M, Bontrop RE, 't Hart B. Modeling human arthritic diseases in nonhuman primates. Arthritis Res Ther. 2005;7:145-54.
23. Vierboom MP, Jonker M, Tak PP, 't Hart BA. Preclinical models of arthritic disease in non-human primates. Drug Discov Today. 2007;12:327-35.
24. Putnam FW, Liu YS, Low TL. Primary structure of a human IgA1 immunoglobulin. IV. Streptococcal IgA1 protease, digestion, Fab and Fc fragments, and the complete amino acid sequence of the alpha 1 heavy chain. J Biol Chem. 1979;254:2865-74.
25. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645-68.
26. Vierboom M, Breedveld E, Kondova I, 't Hart BA. The significance of non-human primates as preclinical models of human arthritic disease. Expert Opin Drug Discov. 2008;3:299-310.
27. Holz JB, Sargentini-Maier L, De Bruyn S, Gachályi B, Udvaros I, Rojkovich B, et al. Twenty-four weeks of treatment with a novel anti-IL-6 receptor Nanobody® (ALX-0061) resulted in 84 % ACR20 improvement and 58 % DAS28 remission in a phase I/II study in RA. Ann Rheum Dis. 2013;72:A64.
28. Owyang AM, Issafras H, Corbin J, Ahluwalia K, Larsen P, Pongo E, et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1beta-mediated diseases. MAbs. 2011;3:49-60.
29. Rathanaswami P, Roalstad S, Roskos L, Su QJ, Lackie S, Babcook J. Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8. Biochem Biophys Res Commun. 2005;334:1004-13.
30. Zunszain PA, Ghuman J, Komatsu T, Tsuchida E, Curry S. Crystal structural analysis of human serum albumin complexed with hemin and fatty acid. BMC Struct Biol. 2003;3:6.
31. Kuo TT, Baker K, Yoshida M, Qiao SW, Aveson VG, Lencer WI, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol. 2010;30:777-89.
32. Clark R, Olson K, Fuh G, Marian M, Mortensen D, Teshima G, et al. Long-acting growth hormones produced by conjugation with polyethylene glycol. J Biol Chem. 1996;271:21969-77.
33. Venkatachalam MA, Rennke HG. The structural and molecular basis of glomerular filtration. Circ Res. 1978;43:337-47.
34. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093-5.
35. Nguyen A, Reyes 2nd AE, Zhang M, McDonald P, Wong WL, Damico LA, et al. The pharmacokinetics of an albumin-binding Fab (AB.Fab) can be modulated as a function of affinity for albumin. Protein Eng Des Sel. 2006;19:291-7.
36. Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010;50:754-66.
37. Shinkura H, Imazeki I, Yamazaki M, Oda Y, Kotoh M, Mihara M. In vivo blocking effects of a humanized antibody to human interleukin-6 receptor on interleukin-6 function in primates. Anticancer Res. 1998;18:1217-21.
38. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
39. Brok HP, Tekoppele JM, Hakimi J, Kerwin JA, Nijenhuis EM, De Groot CW, et al. Prophylactic and therapeutic effects of a humanized monoclonal antibody against the IL-2 receptor (DACLIZUMAB) on collagen-induced arthritis (CIA) in rhesus monkeys. Clin Exp Immunol. 2001;124:134-41.
40. Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol. 1991;147:1352-9.
41. Vierboom M, Breedveld E, Hart B, Coulon F, Vanhove B. Evaluation of selective manipulation of the CD28 co-stimulation pathway in the rhesus monkey model of collagen-induced arthritis (2013). https://ww2.rheumatology.org/apps/MyAnnualMeeting/Abstract/36556 . Accessed 3 June 2015.
42. Shimozuru Y, Yamane S, Fujimoto K, Terao K, Honjo S, Nagai Y, et al. Collagen-induced arthritis in nonhuman primates: multiple epitopes of type II collagen can induce autoimmune-mediated arthritis in outbred cynomolgus monkeys. Arthritis Rheum. 1998;41:507-14.
43. Terato K, Arai H, Shimozuru Y, Fukuda T, Tanaka H, Watanabe H, et al. Sex-linked differences in susceptibility of cynomolgus monkeys to type II collagen-induced arthritis. Evidence that epitope-specific immune suppression is involved in the regulation of type II collagen autoantibody formation. Arthritis Rheum. 1989;32:748-58.
44. Emery P, Gabay C, Kraan M, Gomez-Reino J. Evidence-based review of biologic markers as indicators of disease progression and remission in rheumatoid arthritis. Rheumatol Int. 2007;27:793-806.
45. Heinrich PC, Castell JV, Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990;265:621-36.
46. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58:2968-80.
47. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-29.
48. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:3959-64.